Pharmicell Co., Ltd. (005690.KS)
KRW 8000.0
(0.63%)
KRW 8000.0
(0.63%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 99.19 Billion KRW | -11.98% |
| 2022 | 112.69 Billion KRW | 17.62% |
| 2021 | 95.81 Billion KRW | 37.38% |
| 2020 | 69.74 Billion KRW | 10.24% |
| 2019 | 63.26 Billion KRW | 7.02% |
| 2018 | 59.11 Billion KRW | -7.27% |
| 2017 | 63.75 Billion KRW | -37.47% |
| 2016 | 101.95 Billion KRW | -0.14% |
| 2015 | 102.1 Billion KRW | 3.29% |
| 2014 | 98.84 Billion KRW | -0.53% |
| 2013 | 99.36 Billion KRW | -27.16% |
| 2012 | 136.42 Billion KRW | 34.87% |
| 2011 | 101.15 Billion KRW | 272.44% |
| 2010 | 27.15 Billion KRW | 15.71% |
| 2009 | 23.47 Billion KRW | 47.23% |
| 2008 | 15.94 Billion KRW | -68.88% |
| 2007 | 51.22 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 90.3 Billion KRW | -2.87% |
| 2024 Q1 | 92.98 Billion KRW | -6.26% |
| 2023 Q1 | 113.91 Billion KRW | 1.09% |
| 2023 Q4 | 99.19 Billion KRW | -2.48% |
| 2023 FY | 99.19 Billion KRW | -11.98% |
| 2023 Q2 | 110.87 Billion KRW | -2.67% |
| 2023 Q3 | 101.71 Billion KRW | -8.26% |
| 2022 Q2 | 107.58 Billion KRW | 3.86% |
| 2022 FY | 112.69 Billion KRW | 17.62% |
| 2022 Q4 | 112.69 Billion KRW | -0.49% |
| 2022 Q3 | 113.24 Billion KRW | 5.26% |
| 2022 Q1 | 103.59 Billion KRW | 8.12% |
| 2021 Q1 | 72.29 Billion KRW | 3.66% |
| 2021 Q4 | 95.81 Billion KRW | -2.07% |
| 2021 Q2 | 94.05 Billion KRW | 30.09% |
| 2021 Q3 | 97.84 Billion KRW | 4.03% |
| 2021 FY | 95.81 Billion KRW | 37.38% |
| 2020 FY | 69.74 Billion KRW | 10.24% |
| 2020 Q1 | 64.15 Billion KRW | 1.4% |
| 2020 Q3 | 67.38 Billion KRW | -0.06% |
| 2020 Q4 | 69.74 Billion KRW | 3.5% |
| 2020 Q2 | 67.42 Billion KRW | 5.1% |
| 2019 Q4 | 63.26 Billion KRW | 4.03% |
| 2019 FY | 63.26 Billion KRW | 7.02% |
| 2019 Q3 | 60.81 Billion KRW | 0.7% |
| 2019 Q2 | 60.39 Billion KRW | 1.34% |
| 2019 Q1 | 59.59 Billion KRW | 0.81% |
| 2018 Q4 | 59.11 Billion KRW | -18.23% |
| 2018 Q2 | 71.78 Billion KRW | 9.79% |
| 2018 FY | 59.11 Billion KRW | -7.27% |
| 2018 Q1 | 65.38 Billion KRW | 2.56% |
| 2018 Q3 | 72.3 Billion KRW | 0.72% |
| 2017 Q1 | 101.46 Billion KRW | -0.48% |
| 2017 Q4 | 63.75 Billion KRW | -35.3% |
| 2017 FY | 63.75 Billion KRW | -37.47% |
| 2017 Q3 | 98.53 Billion KRW | -0.98% |
| 2017 Q2 | 99.51 Billion KRW | -1.92% |
| 2016 Q2 | 101.13 Billion KRW | -1.55% |
| 2016 Q4 | 101.95 Billion KRW | -1.04% |
| 2016 FY | 101.95 Billion KRW | -0.14% |
| 2016 Q3 | 103.02 Billion KRW | 1.87% |
| 2016 Q1 | 102.72 Billion KRW | 0.61% |
| 2015 Q2 | 100.74 Billion KRW | -0.71% |
| 2015 FY | 102.1 Billion KRW | 3.29% |
| 2015 Q4 | 102.1 Billion KRW | 0.86% |
| 2015 Q3 | 101.22 Billion KRW | 0.48% |
| 2015 Q1 | 101.46 Billion KRW | 2.65% |
| 2014 FY | 98.84 Billion KRW | -0.53% |
| 2014 Q3 | 105.3 Billion KRW | 3.06% |
| 2014 Q2 | 102.17 Billion KRW | 1.02% |
| 2014 Q1 | 101.14 Billion KRW | 1.79% |
| 2014 Q4 | 98.84 Billion KRW | -6.13% |
| 2013 Q3 | 132.59 Billion KRW | 1.24% |
| 2013 Q4 | 99.36 Billion KRW | -25.06% |
| 2013 Q2 | 130.96 Billion KRW | -0.54% |
| 2013 Q1 | 131.67 Billion KRW | -3.48% |
| 2013 FY | 99.36 Billion KRW | -27.16% |
| 2012 FY | 136.42 Billion KRW | 34.87% |
| 2012 Q4 | 136.42 Billion KRW | 0.0% |
| 2012 Q1 | 99.41 Billion KRW | 0.0% |
| 2011 Q3 | 98.53 Billion KRW | 230.1% |
| 2011 Q2 | 29.84 Billion KRW | -8.15% |
| 2011 Q1 | 32.49 Billion KRW | 19.65% |
| 2011 FY | 101.15 Billion KRW | 272.44% |
| 2010 Q1 | 22.81 Billion KRW | -2.8% |
| 2010 Q4 | 27.15 Billion KRW | -3.32% |
| 2010 FY | 27.15 Billion KRW | 15.71% |
| 2010 Q2 | 21.1 Billion KRW | -7.52% |
| 2010 Q3 | 28.09 Billion KRW | 33.14% |
| 2009 Q3 | 25.3 Billion KRW | 85.12% |
| 2009 Q2 | 13.66 Billion KRW | 3.85% |
| 2009 Q1 | 13.16 Billion KRW | -17.44% |
| 2009 FY | 23.47 Billion KRW | 47.23% |
| 2009 Q4 | 23.47 Billion KRW | -7.24% |
| 2008 Q1 | 49.48 Billion KRW | -3.41% |
| 2008 Q4 | 15.94 Billion KRW | -74.31% |
| 2008 FY | 15.94 Billion KRW | -68.88% |
| 2008 Q2 | 49.26 Billion KRW | -0.44% |
| 2008 Q3 | 62.07 Billion KRW | 25.99% |
| 2007 FY | 51.22 Billion KRW | 0.0% |
| 2007 Q4 | 51.22 Billion KRW | 0.47% |
| 2007 Q3 | 50.98 Billion KRW | 1.48% |
| 2007 Q2 | 50.24 Billion KRW | 0.1% |
| 2007 Q1 | 50.19 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ORIENT BIO Inc. | 96.98 Billion KRW | -2.272% |
| Green Cross Holdings Corporation | 3737.7 Billion KRW | 97.346% |
| Green Cross Holdings Corporation | 2643.31 Billion KRW | 96.247% |
| Green Cross Corporation | 2643.31 Billion KRW | 96.247% |
| GeneOne Life Science, Inc. | 151 Billion KRW | 34.314% |
| Celltrion, Inc. | 19917.53 Billion KRW | 99.502% |
| Samsung Biologics Co.,Ltd. | 16046.19 Billion KRW | 99.382% |
| SK bioscience Co.,Ltd. | 1852.43 Billion KRW | 94.645% |
| SK Biopharmaceuticals Co., Ltd. | 723.17 Billion KRW | 86.284% |
| Prestige BioPharma Limited | 711.72 Billion KRW | 86.063% |